| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Not applicable. N-Demethyl lincomycin hydrochloride is a degraded impurity and does not have a specific biological target for therapy. Lincomycin itself targets the bacterial 50S ribosomal subunit, inhibiting protein synthesis. This N-demethylated analog is significantly less potent as an antibiotic due to the altered chemical structure, which may reduce its binding affinity to the ribosome. It is not used to treat bacterial infections. Its role is strictly as a chemical marker for the purity of lincomycin.
|
|---|---|
| ln Vitro |
In vitro, this compound is not used for biological activity. It is an analytical standard. In an HPLC method for lincomycin, a system suitability solution is prepared containing lincomycin (1 mg/mL) and the impurity at 0.5-1.0 ug/mL. The solution is injected into a C18 column with a mobile phase of 0.05 M borax buffer (pH 8.0) and methanol (50:50). UV detection is performed at 210 nm. The relative retention time (RRT) of this impurity is specific and used to confirm that the analytical method can separate it from the main peak. It does not exhibit significant antibacterial activity against standard strains like S. aureus.
|
| ln Vivo |
In vivo, this compound is not administered to animals. It is studied in the context of pharmacokinetics only as a metabolite. When lincomycin is administered to rats, this impurity can sometimes be detected in plasma, but it is not used for efficacy. In quality control, stability samples of lincomycin are analyzed to ensure that this impurity level remains below the regulatory limit (usually <1%). It is not used in disease models.
|
| Enzyme Assay |
General protocol for in vitro analytical use: For HPLC analysis of Lincomycin impurities, prepare mobile phase: 0.05 M borax buffer (pH 8.0) and methanol (50:50). Prepare a stock solution of the impurity (1 mg/mL) in water. Prepare a system suitability solution containing lincomycin (2 mg/mL) and the impurity (2 ug/mL). Inject 20 uL onto a C18 column (4.6 × 250 mm, 5 um) at 40degC. Flow rate: 1.0 mL/min. UV detection at 210 nm. The retention time of lincomycin is approximately 12 min, and the impurity elutes with a RRT of about 0.85. Validate the method for specificity, linearity (0.1-10 ug/mL), and accuracy. The reference standard is stored at -20degC. For LC-MS, use positive mode with m/z 429 [M+H]+.
|
| Cell Assay |
General protocol for in vitro cell-based experiments: For a forced degradation study, expose lincomycin API (10 mg) to heat (60degC, 72 h) in an oven. Analyze by HPLC. Compare the impurity profile to a fresh sample. The peak for the impurity will increase due to thermal degradation. No cell culture is required.
|
| Animal Protocol |
General protocol for in vivo animal experiments: For a pharmacokinetic study of lincomycin (not the impurity), administer lincomycin (50 mg/kg, IM) to rats. Collect plasma at 0.5, 1, 2, 4, 6, 8 h. Add internal standard. Extract with acetonitrile. Analyze by LC-MS/MS. Monitor the precursor-product ion transitions for lincomycin and the impurity. Quantify the levels of the impurity to determine if it is a circulating metabolite. This is a metabolism study, not an efficacy model.
|
| ADME/Pharmacokinetics |
General pharmacokinetic properties: This compound is the HCl salt of a small molecule (free base MW 392.51). It is a polar compound. It is soluble in water and methanol. It is not a drug, so no dedicated ADME data exists. As an impurity, its concentration is kept low. For storage, the powder is stable at 2-8degC for up to 3 years. The standard is used for quality control. It is an impurity of Lincomycin and is known as Lincomycin EP Impurity D. The product is for analytical and research purposes only and not for human consumption. It is a white to off-white solid.
|
| Toxicity/Toxicokinetics |
General toxicity profile: This compound is an impurity and is not considered highly toxic at the trace levels present in drug products. However, as an impurity, it must be controlled. Standard safety precautions for handling chemical standards (gloves, lab coat) should be used. It is a research chemical and is not for human or veterinary use. The product is for research and quality control use only. It is a degradation product of lincomycin and is used to monitor the stability of the drug substance. For long-term storage, keep at -20degC in a sealed container.
|
| Molecular Formula |
C17H33CLN2O6S
|
|---|---|
| Molecular Weight |
428.97
|
| Exact Mass |
428.175
|
| CAS # |
14600-41-0
|
| PubChem CID |
169437323
|
| Appearance |
Typically exists as solids at room temperature
|
| Hydrogen Bond Donor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
27
|
| Complexity |
471
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
CCC[C@@H]1C[C@H](NC1)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O.Cl
|
| InChi Key |
CHKUTFKCSCMSCE-NLBLSBHASA-N
|
| InChi Code |
InChI=1S/C17H32N2O6S.ClH/c1-4-5-9-6-10(18-7-9)16(24)19-11(8(2)20)15-13(22)12(21)14(23)17(25-15)26-3;/h8-15,17-18,20-23H,4-7H2,1-3H3,(H,19,24);1H/t8-,9-,10+,11-,12+,13-,14-,15-,17-;/m1./s1
|
| Chemical Name |
(2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-4-propylpyrrolidine-2-carboxamide;hydrochloride
|
| Synonyms |
4'-Propyl-N-demethyllincomycin hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3312 mL | 11.6558 mL | 23.3117 mL | |
| 5 mM | 0.4662 mL | 2.3312 mL | 4.6623 mL | |
| 10 mM | 0.2331 mL | 1.1656 mL | 2.3312 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
